Compare FSI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | IMUX |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 85.8M |
| IPO Year | 1999 | N/A |
| Metric | FSI | IMUX |
|---|---|---|
| Price | $6.10 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 32.7K | ★ 1.7M |
| Earning Date | 11-14-2025 | 02-14-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $38,563,427.00 | N/A |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $53.12 | N/A |
| P/E Ratio | $44.08 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $3.46 | $0.51 |
| 52 Week High | $11.48 | $1.39 |
| Indicator | FSI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 48.52 |
| Support Level | $6.60 | $0.64 |
| Resistance Level | $6.96 | $0.71 |
| Average True Range (ATR) | 0.40 | 0.05 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 40.85 | 57.76 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.